Real world data regarding the management of cancer-associated thrombosis
Affiliation
Department of Oncology, 401 Military Hospital of Athens, Athens.Issue Date
2020
Metadata
Show full item recordAbstract
Purpose of review: Patients with cancer are at high risk for thrombotic events, mainly deep vein thrombosis and pulmonary embolism. Low-molecular-weight heparins (LMWHs) and direct oral anticoagulants (DOACs) are among the current treatment options for cancer-associated thrombosis (CAT). We assessed real world data (RWD) regarding treatment patterns of CAT from 1 September 2018 to 31 January 2020. Recent findings: RWD showed that LMWHs were the most common initial anticoagulation treatment for CAT. Based on these data DOACs had a lower risk of recurrent venous thromboembolism compared with LMWHs and warfarin. However, the selection bias and the small number of patients in these studies might explain this difference and these limitations should be taken into consideration. Moreover, there was no statistical difference regarding adverse events during anticoagulant treatment between LMWHs and DOACs with the limitations of RWD. As far as the duration of the treatment is concerned, the adherence ranged from 100% to 67.3% at 6 months. Summary: The current review of RWD illustrates that LMWHs and DOACs are used for the treatment of CAT. LMWHs are most commonly used for the initial management of CAT. Data regarding recurrence of CAT, adverse events, compliance and duration of anticoagulant treatment should be analyzed with caution as RWD are observational studies with many limitations. Further research is needed to elucidate the best algorithm for the management of CAT.Citation
Tsoukalas N, Tsapakidis K, Galanopoulos M, Karamitrousis E, Kamposioras K, Tolia M. Real world data regarding the management of cancer-associated thrombosis. Curr Opin Oncol. 2020;32(4):289-94.Journal
Current Opinion in OncologyDOI
10.1097/cco.0000000000000646PubMed ID
32541315Additional Links
https://dx.doi.org/10.1097/cco.0000000000000646Type
ArticleLanguage
enae974a485f413a2113503eed53cd6c53
10.1097/cco.0000000000000646
Scopus Count
Collections
Related articles
- Anticoagulation for the long-term treatment of venous thromboembolism in people with cancer.
- Authors: Kahale LA, Hakoum MB, Tsolakian IG, Matar CF, Terrenato I, Sperati F, Barba M, Yosuico VE, Schünemann H, Akl EA
- Issue date: 2018 Jun 19
- Efficacy and safety of anticoagulant agents in patients with venous thromboembolism and cancer: A network meta-analysis.
- Authors: Vedovati MC, Giustozzi M, Bonitta G, Agnelli G, Becattini C
- Issue date: 2018 Oct
- The Role of Direct Oral Anticoagulants in Cancer-Associated Thrombosis According to the Current Literature.
- Authors: Nana P, Dakis K, Peroulis M, Rousas N, Spanos K, Kouvelos G, Arnaoutoglou E, Matsagkas M
- Issue date: 2021 Sep 12
- Management of cancer-associated venous thromboembolism - a case-based practical approach.
- Authors: Voigtlaender M, Langer F
- Issue date: 2018 Feb
- Clinical course of isolated distal deep vein thrombosis in patients with active cancer: a multicenter cohort study.
- Authors: Dentali F, Pegoraro S, Barco S, di Minno MND, Mastroiacovo D, Pomero F, Lodigiani C, Bagna F, Sartori M, Barillari G, Mumoli N, Napolitano M, Passamonti SM, Benedetti R, Ageno W, Di Nisio M
- Issue date: 2017 Sep